Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN
01:30pm, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN). Such investors are advised
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning possible
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN
01:00pm, Monday, 03'rd Mar 2025
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to cont
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning possible
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Geron Corporation ("Geron Corporation") (NASDAQ:GERN) concerning poss
Kirby McInerney LLP Announces Investigation Against Geron Corporation (GERN) on Behalf of Investors
08:00pm, Thursday, 27'th Feb 2025
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN). The invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN
08:28pm, Wednesday, 26'th Feb 2025
NEW YORK , Feb. 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to
Why Geron Stock Is Plummeting Today
04:02pm, Wednesday, 26'th Feb 2025
Geron (GERN -31.43%) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m.
Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales
12:12pm, Wednesday, 26'th Feb 2025
Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new patients starts flat. Rytelo's market share in second-line LR-MDS is lower
Geron Corporation (GERN) Q4 2024 Earnings Call Transcript
11:31am, Wednesday, 26'th Feb 2025
Geron Corporation (NASDAQ:GERN ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman and C
Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates
09:40am, Wednesday, 26'th Feb 2025
Geron (GERN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.09 per share a year ago.
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
07:30am, Wednesday, 26'th Feb 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan
3 Biotech/Healthcare Names Under $10 I Am Buying Now
04:21pm, Friday, 21'st Feb 2025
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equ
Geron to Participate at Upcoming Investor Conferences in March 2025
09:00am, Friday, 21'st Feb 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate i
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 19'th Feb 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000
